Decision and Details
United States Patent and Trademark OfficeNotice of allowance for a new patent covering the treatment of glioblastoma using combination therapy with MN-166 (ibudilast) and a PD-1 antibody, an immune checkpoint inhibitor
To strengthen the intellectual property foundation for combination therapies related to the Company's development strategy, and to further strengthen the intellectual property portfolio for MN-166 in the field of central nervous system tumors.
The impact on results for the fiscal year ending December 2026 is expected to be minor.
| Item | Details |
|---|---|
| Matter Covered | Notice of allowance for a new patent covering the treatment of glioblastoma using combination therapy with MN-166 (ibudilast) and a PD-1 antibody, an immune checkpoint inhibitor |
| Decision-Making Body | United States Patent and Trademark Office |
| Decision Date | 8 June 2026 (date the notice was received) |
| Period Covered | At least through September 2042 (patent validity period) |
| Quantity / scale | A broad range of treatment conditions, including treatment duration, dosing frequency, route of administration, dosage and dosing schedules; combinations with multiple anti-PD-1 antibodies |
| Impact on Business Performance | The impact on results for the fiscal year ending December 2026 is expected to be minor. |
| Reason | To strengthen the intellectual property foundation for combination therapies related to the Company's development strategy, and to further strengthen the intellectual property portfolio for MN-166 in the field of central nervous system tumors. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen the intellectual property foundation for combination therapies related to the Company's development strategy.